Payment overview · 2025
General Payments
$267.95
13 reported records · 9 companies
Healthcare provider profile · identity verified
Dane D Simons, MD
Allopathic & Osteopathic Physicians|General Practice · BAY CITY, TX · NPI 1609876283
Verified facts
What the public records show
CMS Open Payments records show Dane D Simons, MD received $267.95 in general payments during 2025 across 13 reported records.
Axsome Therapeutics, Inc. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $58.20 | 21.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.82 | 18.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.73 | 17.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.29 | 8.3% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $21.10 | 7.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.90 | 7.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.46 | 6.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.45 | 6.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.00 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.95 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $58.20 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.82 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.73 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $26.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 125 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 394 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 81 |
| Montelukast Sodium | Montelukast Sodium | 297 | 92 |
| Metformin Hcl | Metformin Hcl | 275 | 76 |
| Diclofenac Sodium | Diclofenac Sodium | 273 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 66 |
| Gabapentin | Gabapentin | 261 | 57 |
| Lisinopril | Lisinopril | 246 | 75 |
| Alprazolam | Alprazolam | 239 | 41 |
| Clonazepam | Clonazepam | 213 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 48 |
| Glimepiride | Glimepiride | 181 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 48 |
| Furosemide | Furosemide | 170 | 40 |
| Tramadol Hcl | Tramadol Hcl | 166 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 50 |
| Meloxicam | Meloxicam | 146 | 38 |
| Omeprazole | Omeprazole | 145 | 38 |
| Piroxicam | Piroxicam | 142 | 44 |
| Losartan Potassium | Losartan Potassium | 139 | 41 |
| Celecoxib | Celecoxib | 127 | 25 |
| Trazodone Hcl | Trazodone Hcl | 118 | 25 |
| Levofloxacin | Levofloxacin | 110 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 106 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 104 | 29 |
| Eliquis | Apixaban | 99 | 18 |
| Ozempic | Semaglutide | 97 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 89 | 30 |
| Doxepin Hcl | Doxepin Hcl | 87 | 14 |
| Ezetimibe | Ezetimibe | 87 | 22 |
| Azithromycin | Azithromycin | 85 | 73 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 37 |
| Simvastatin | Simvastatin | 83 | 24 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 82 | 26 |
| Methocarbamol | Methocarbamol | 80 | 34 |
| Lorazepam | Lorazepam | 77 | 14 |
| Prednisone | Prednisone | 75 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 15 |
| Finasteride | Finasteride | 74 | 20 |
| Potassium Chloride | Potassium Chloride | 74 | 15 |
| Spironolactone | Spironolactone | 74 | 20 |
| Clonidine Hcl | Clonidine Hcl | 68 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 24 |
| Allopurinol | Allopurinol | 66 | 15 |
| Cefdinir | Cefdinir | 66 | 44 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 18 |
| Mupirocin | Mupirocin | 60 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 15 |
| Donepezil Hcl | Donepezil Hcl | 59 | 12 |
| Farxiga | Dapagliflozin Propanediol | 58 | 15 |
| Pregabalin | Pregabalin | 56 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 13 |
| Famotidine | Famotidine | 50 | suppressed |
| Ondansetron Odt | Ondansetron | 50 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 27 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 16 |
| Torsemide | Torsemide | 46 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Atenolol | Atenolol | 39 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 39 | 16 |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Baclofen | Baclofen | 36 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 30 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Carvedilol | Carvedilol | 35 | 11 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 17 |
| Armour Thyroid | Thyroid,pork | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Dexamethasone | Dexamethasone | 29 | 29 |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 17 |
| Glipizide | Glipizide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Niacin Er | Niacin | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 16 |
| Lumigan | Bimatoprost | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 12 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 16 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 15 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.95 · 13 records | Axsome Therapeutics, Inc. | Auvelity, CAPVAXIVE, CONTRAVE, GARDASIL 9, JARDIANCE, JATENZO, Kerendia, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error